MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma

Oncogene

Volumn 31, Issue 38, 2012, Pages 4221-4232

  Rothschild, S I ^a,b   Tschan, M P ^a   Federzoni, E A ^a   Jaggi, R ^a   Fey, M F ^a   Gugger, M ^a   Gautschi, O ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Luzerner Kantonsspital   (Switzerland)

Author keywords

c Myc; ID1; inhibitor of differentiation protein 1; lung cancer; miR 29b; Src

Indexed keywords

COMPLEMENTARY RNA; DASATINIB; INHIBITOR OF DIFFERENTIATION 1; LUCIFERASE; MESSENGER RNA; MICRORNA 29B; SARACATINIB;

3' UNTRANSLATED REGION; ARTICLE; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; ONCOGENE C MYC; ONCOGENE SRC; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UPREGULATION;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LUNG NEOPLASMS; MICRORNAS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84866541922     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.578     Document Type: Article

References (50)

1. Albini A, Benelli R. (2007). The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2: 504-511. (Pubitemid 47040014)
2. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH. (2010). Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 16: 610-619.
3. Caldas C, Brenton JD. (2005). Sizing up miRNAs as cancer genes. Nat Med 11: 712-714. (Pubitemid 41021196)
4. Calin GA, Croce CM. (2006). MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66: 7390-7394. (Pubitemid 44289189)
5. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. (2005). A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801. (Pubitemid 41549891)
6. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004. (Pubitemid 38327724)
7. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. (2008a). Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50.
8. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. (2008b). Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 27: 6365-6375.
9. Croce CM. (2009). Causes and consequences of microRNA dysregula-tion in cancer. Nat Rev Genet 10: 704-714.
10. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. (2007). MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104: 15805-15810. (Pubitemid 350035380)
11. Fong S, Debs RJ, Desprez PY. (2004). Id genes and proteins as promising targets in cancer therapy. Trends Mol Med 10: 387-392. (Pubitemid 39061140)
12. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C et al. (2008). Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 105: 3945-3950. (Pubitemid 351723504)
13. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP et al. (2008). Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res 68: 2250-2258. (Pubitemid 351521798)
14. Geback T, Schulz MM, Koumoutsakos P, Detmar M. (2009). TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques 46: 265-274.
15. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. (2006). miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-D144.
16. Guo H, Ingolia NT, Weissman JS, Bartel DP. (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840.
17. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070. (Pubitemid 41161233)
18. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. (2004). Human MicroRNA targets. PLoS Biol 2: e363.
19. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT et al. (2010). Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 28: 4609-4615.
20. Kaeser MD, Iggo RD. (2002). Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 99: 95-100. (Pubitemid 34060322)
21. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. (2005). Combinatorial microRNA target predictions. Nat Genet 37: 495-500. (Pubitemid 40617277)
22. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J. (2003). The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24: 1445-1454. (Pubitemid 37160834)
23. Lasorella A, Uo T, Iavarone A. (2001). Id proteins at the cross-road of development and cancer. Oncogene 20: 8326-8333. (Pubitemid 34121903)
24. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K et al. (2009). Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 27: 2030-2037.
25. Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A et al. (2005). Randomized phase III study of matrix metallopro-teinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR 18. J Clin Oncol 23: 2831-2839. (Pubitemid 46179474)
26. Lewis BP, Burge CB, Bartel DP. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20. (Pubitemid 40094598)
27. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
28. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R et al. (1999). Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401: 670-677.
29. McCarty Jr KS, Miller LS, Cox EB, Konrath J, McCarty Sr KS. (1985). Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109: 716-721. (Pubitemid 16237466)
30. Mitra SK, Schlaepfer DD. (2006). Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18: 516-523. (Pubitemid 44332916)
31. Mott JL, Kobayashi S, Bronk SF, Gores GJ. (2007). mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26: 6133-6140. (Pubitemid 47414372)
32. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME. (2010). Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 110: 1155-1164.
33. Muniyappa MK, Dowling P, Henry M, Meleady P, Doolan P, Gammell P et al. (2009). MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur J Cancer 45: 3104-3118.
34. Oberli A, Popovici V, Delorenzi M, Baltzer A, Antonov J, Matthey S et al. (2008). Expression profiling with RNA from formalin-fixed, paraffin-embedded material. BMC Med Genomics 1: 9.
35. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. (2010). Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 70: 36-45.
36. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V et al. (2006). Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 66: 11590-11593. (Pubitemid 46094168)
37. Rothschild SI, Gautschi O, Haura EB, Johnson FM. (2010). Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer 11: 238-242.
38. Rothschild SI, Kappeler A, Ratschiller D, Betticher DC, Tschan MP, Gugger M et al. (2011). The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer. Lung Cancer 71: 306-311.
39. Summy JM, Gallick GE. (2006). Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 12: 1398-1401.
40. Sun X, Li C, Zhuang C, Gilmore WC, Cobos E, Tao Y et al. (2009). Abl interactor 1 regulates Src-Id1-matrix metalloproteinase 9 axis and is required for invadopodia formation, extracellular matrix degradation and tumor growth of human breast cancer cells. Carcinogenesis 30: 2109-2116.
41. Swarbrick A, Akerfeldt MC, Lee CS, Sergio CM, Caldon CE, Hunter LJ et al. (2005). Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1. Oncogene 24: 381-389. (Pubitemid 40188586)
42. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756. (Pubitemid 38697282)
43. Tschan MP, Fischer KM, Fung VS, Pirnia F, Borner MM, Fey MF et al. (2003). Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns. J Biol Chem 278: 42750-42760. (Pubitemid 37345884)
44. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. (2006). Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20: 515-524. (Pubitemid 43345317)
45. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M et al. (2010). MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 70: 8288-8298.
46. Wu X, Piper-Hunter MG, Crawford M, Nuovo GJ, Marsh CB, Otterson GA et al. (2009). MicroRNAs in the pathogenesis of Lung Cancer. J Thorac Oncol 4: 1028-1034.
47. Xu H, Cheung IY, Guo HF, Cheung NK. (2009). MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 69: 6275-6281.
48. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198. (Pubitemid 43357945)
49. Yokota Y. (2001). Id and development. Oncogene 20: 8290-8298. (Pubitemid 34121899)
50. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S et al. (2008). MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48-57. (Pubitemid 350309743)